Bone Sclerostin and Dickkopf-related protein-1 are positively correlated with bone mineral density, bone microarchitecture, and bone strength in postmenopausal osteoporosis

[1] Jäckle K(2020)Analysis of low-dose estrogen on callus BMD as measured by pQCT in postmenopausal women BMC Musculoskelet Disord 21 1-34

[2] Kolb JP(2014)Osteocyte-driven bone remodeling Calcif Tissue Int 94 25-690

[3] Schilling AF(2013)The Osteocyte: an endocrine cell … and more Endocr Rev 34 658-132

[4] Schlickewei C(2013)Involvement of WNT/beta-catenin signaling in the treatment of osteoporosis Calcif Tissue Int 93 121-1296

[5] Amling M(2006)Wnt signalling in osteoblasts regulates expression of the receptor activator of NFkappaB ligand and inhibits osteoclastogenesis in vitro J Cell Sci 119 1283-764

[6] Rueger JM(2005)Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation Dev Cell 8 751-16758

[7] Lehmann W(2015)The Wnt inhibitor Sclerostin is up-regulated by mechanical unloading in osteocytes in vitro J Biol Chem 290 16744-589

[8] Bellido T(2001)Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein Am J Hum Genet 68 577-6276

[9] Dallas SL(2003)Osteocyte control of bone formation via sclerostin, a novel BMP antagonist EMBO J 22 6267-1021

[10] Prideaux M(2015)Effect of recent spinal cord injury on wnt signaling antagonists (sclerostin and dkk-1) and their relationship with bone loss. A 12-month prospective study J Bone Miner Res 30 1014-456

[1] Jäckle K(2020)Analysis of low-dose estrogen on callus BMD as measured by pQCT in postmenopausal women BMC Musculoskelet Disord 21 1-34

[2] Kolb JP(2014)Osteocyte-driven bone remodeling Calcif Tissue Int 94 25-690

[3] Schilling AF(2013)The Osteocyte: an endocrine cell … and more Endocr Rev 34 658-132

[4] Schlickewei C(2013)Involvement of WNT/beta-catenin signaling in the treatment of osteoporosis Calcif Tissue Int 93 121-1296

[5] Amling M(2006)Wnt signalling in osteoblasts regulates expression of the receptor activator of NFkappaB ligand and inhibits osteoclastogenesis in vitro J Cell Sci 119 1283-764

[6] Rueger JM(2005)Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation Dev Cell 8 751-16758

[7] Lehmann W(2015)The Wnt inhibitor Sclerostin is up-regulated by mechanical unloading in osteocytes in vitro J Biol Chem 290 16744-589

[8] Bellido T(2001)Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein Am J Hum Genet 68 577-6276

[9] Dallas SL(2003)Osteocyte control of bone formation via sclerostin, a novel BMP antagonist EMBO J 22 6267-1021

[10] Prideaux M(2015)Effect of recent spinal cord injury on wnt signaling antagonists (sclerostin and dkk-1) and their relationship with bone loss. A 12-month prospective study J Bone Miner Res 30 1014-456